261 related articles for article (PubMed ID: 7880735)
21. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.
Kyle AH; Minchinton AI
Cancer Chemother Pharmacol; 1999; 43(3):213-20. PubMed ID: 9923551
[TBL] [Abstract][Full Text] [Related]
22. Reoxygenation and rehypoxiation in the SCCVII mouse tumor.
Kim IH; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):493-7. PubMed ID: 8005805
[TBL] [Abstract][Full Text] [Related]
23. Hydroethidine: a fluorescent redox probe for locating hypoxic cells in spheroids and murine tumours.
Olive PL
Br J Cancer; 1989 Sep; 60(3):332-8. PubMed ID: 2789941
[TBL] [Abstract][Full Text] [Related]
24. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
25. Detection of hypoxic cells in a murine tumor with the use of the comet assay.
Olive PL; Durand RE
J Natl Cancer Inst; 1992 May; 84(9):707-11. PubMed ID: 1569605
[TBL] [Abstract][Full Text] [Related]
26. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions.
Hwang JT; Greenberg MM; Fuchs T; Gates KS
Biochemistry; 1999 Oct; 38(43):14248-55. PubMed ID: 10571998
[TBL] [Abstract][Full Text] [Related]
27. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
Dorie MJ; Kovacs MS; Gabalski EC; Adam M; Le QT; Bloch DA; Pinto HA; Terris DJ; Brown JM
Neoplasia; 1999 Nov; 1(5):461-7. PubMed ID: 10933062
[TBL] [Abstract][Full Text] [Related]
28. Dual action of tirapazamine in the induction of DNA strand breaks.
Jones GD; Weinfeld M
Cancer Res; 1996 Apr; 56(7):1584-90. PubMed ID: 8603406
[TBL] [Abstract][Full Text] [Related]
29. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation.
Wang J; Biedermann KA; Brown JM
Cancer Res; 1992 Aug; 52(16):4473-7. PubMed ID: 1643639
[TBL] [Abstract][Full Text] [Related]
30. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
Denny WA; Wilson WR
Expert Opin Investig Drugs; 2000 Dec; 9(12):2889-901. PubMed ID: 11093359
[TBL] [Abstract][Full Text] [Related]
31. Radiation-induced reoxygenation in the SCCVII murine tumour: evidence for a decrease in oxygen consumption and an increase in tumour perfusion.
Olive PL
Radiother Oncol; 1994 Jul; 32(1):37-46. PubMed ID: 7938677
[TBL] [Abstract][Full Text] [Related]
32. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks.
Banáth JP; Olive PL
Cancer Res; 2003 Aug; 63(15):4347-50. PubMed ID: 12907603
[TBL] [Abstract][Full Text] [Related]
33. Pre- and post-irradiation radiosensitization by SR 4233.
Zeman EM; Brown JM
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):967-71. PubMed ID: 2703404
[TBL] [Abstract][Full Text] [Related]
34. Cell killing and DNA damage by etoposide in Chinese hamster V79 monolayers and spheroids: influence of growth kinetics, growth environment and DNA packaging.
Olive PL; Banáth JP; Evans HH
Br J Cancer; 1993 Mar; 67(3):522-30. PubMed ID: 8382510
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of bioreductive drugs in multicell spheroids.
Durand RE; Olive PL
Int J Radiat Oncol Biol Phys; 1992; 22(4):689-92. PubMed ID: 1544838
[TBL] [Abstract][Full Text] [Related]
36. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
37. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.
Hicks KO; Fleming Y; Siim BG; Koch CJ; Wilson WR
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):641-9. PubMed ID: 9806526
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
[TBL] [Abstract][Full Text] [Related]
39. Genotoxic effects of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and nitrogen mustard-N-oxide (nitromin) in Walker carcinoma cells under aerobic and hypoxic conditions.
Cahill A; Jenkins TC; Pickering P; White IN
Chem Biol Interact; 1995 Mar; 95(1-2):97-107. PubMed ID: 7697757
[TBL] [Abstract][Full Text] [Related]
40. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Abe M
Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
